Septerna Inc. (SEPN)
SEPN trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1984086/000119312526098507/0001193125-26-098507-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | SEPN on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2024 |
| SEC CIK | 0001984086 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $46.0M |
| Net income | -$48.9M |
| Operating income | -$68.3M |
| Net margin | -106.4% |
| Operating margin | -148.6% |
| Revenue growth | +4174.5% |
| Cash | $120.7M |
| Total assets | $596.2M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 43.1× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-09 |
| Cash and burn | $167.1M cash; operating cash flow -$19.1M a quarter. | Report 2026-09-30 |
| Shares outstanding | 47,549,223 (2026-11-04); 44,774,192 a year earlier. | Cover page 2026-11-04 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 0 424B5 takedowns | Latest 2026-03-10 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Ernst & Young LLP, San Mateo, California, United States | PCAOB Form AP 2026-03-25 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $44.3M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $18.9M | -$26.6M | -$13.8M | $167.1M | No debt tags | $96.3M | 10-Q 2026-11-09 |
| Q2 2026 2026-06-30 | $26.7M | -$13.0M | -$22.2M | $84.7M | No debt tags | $98.9M | 10-Q 2026-08-10 |
| Q1 2026 2026-03-31 | $26.5M | -$8.6M | -$25.6M | $71.6M | No debt tags | $72.3M | 10-Q 2026-05-11 |
| Q4 2025 2025-12-31 | $24.1M | -$10.7M | -$15.0M | $120.7M | No debt tags | $46.0M | 10-K 2026-03-09 |
| Q3 2025 2025-09-30 | $21.5M | $8.2M | $168.8M | $320.0M | No debt tags | $22.0M | 10-Q 2026-11-09 |
| Q2 2025 2025-06-30 | $119K | -$24.8M | -$20.3M | $189.3M | No debt tags | $726K | 10-Q 2026-08-10 |
| Q1 2025 2025-03-31 | $219K | -$21.5M | -$23.3M | $210.0M | No debt tags | $977K | 10-Q 2026-05-11 |
| Q4 2024 2024-12-31 | $212K | -$20.7M | -$21.0M | $238.2M | No debt tags | $1.1M | 10-K 2026-03-09 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3ASR | 2026-03-10 |
| Latest annual report | 10-K | 2026-03-09 |
| Latest quarterly / interim | 10-Q | 2026-11-09 |
| Latest current report | 8-K | 2026-11-09 |
| Latest proxy | DEFA14A | 2026-04-30 |
Source: SEC EDGAR submissions feed, 179 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -12.8% |
| 1 month | +17.0% |
| 3 months | -5.6% |
| Year to date | +52.8% |
| 1 year | +121.4% |
| From 52-week high | -18.6% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| TRAX | First Tracks Biotherapeutics Inc. Ordinary Shares | $46.56 | -1.15% | $2.0B |
| VERA | Vera Therapeutics Inc. | $26.97 | -4.02% | $1.9B |
| HRMY | Harmony Biosciences Holdings Inc. | $32.96 | -2.37% | $1.9B |
| MRVI | Maravai LifeSciences Holdings Inc. | $7.40 | -1.86% | $1.9B |
| SDGR | Schrodinger Inc. | $27.36 | -7.35% | $2.1B |
| TRVI | Trevi Therapeutics Inc. | $13.29 | -2.64% | $1.9B |
| ZBIO | Zenas BioPharma Inc. | $27.93 | -0.29% | $1.9B |
| AUPH | Aurinia Pharmaceuticals Inc | $15.48 | -1.59% | $2.1B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier